Repeat that, ammonium.

Ammonium tetra thiomalipidate.

So four thiol groups or four sulfa groups.

So this drug was developed about 40 years ago to treat Wilson's disease.

So for the audience out there, Wilson's disease is a rare genetic disorder that affects about one in 30,000 individuals.

And free copper ions get stored in their liver and brain, and they'll die of copper toxicity unless they chelate it off.

So this is an oral drug.

So is that how do you approach that dietary component with your patients?

Repeat that, ammonium.

Ammonium tetra thiomalipidate.

So four thiol groups or four sulfa groups.

So this drug was developed about 40 years ago to treat Wilson's disease.

So for the audience out there, Wilson's disease is a rare genetic disorder that affects about one in 30,000 individuals.

And free copper ions get stored in their liver and brain, and they'll die of copper toxicity unless they chelate it off.

So this is an oral drug.

So is that how do you approach that dietary component with your patients?

But

if there's no valuable intellectual property on it, these substances will simply not be studied.

And and that's that's very disappointing.

Now, in addition, there are drugs where there is there there is IP on it.

But it's obviously there's so much bureaucracy in many governments and certainly the United States.

And it's very expensive.

So what I did is I brought a drug to Harvard because we have no drug to target cancer stem cells.

All

He didn't speak English.

Yes, that's my point.

He didn't speak English.

But the place was rocking with the energy that's coming from the creativity of the Jewish people in Israel.

A French immigrant.

He was from France and immigrated and learned Hebrew and wrote these beautiful songs that weave together our prayer book and our history all together.

So it is inspiring and connecting people and inspiring their lives.

People